SEQUENOM Announces Sale of Three Additional MassARRAY(TM) Systems, Increasing Customer Installed Base of Systems to 29 Worldwide

Apr 04, 2001, 01:00 ET from SEQUENOM, Inc.

    SAN DIEGO, April 4 /PRNewswire/ -- SEQUENOM(TM), Inc. (Nasdaq: SQNM) today
 announced that it has sold three additional MassARRAY systems, increasing the
 Company's installed base of systems at customer sites to 29 worldwide.  The
 three additional sales include the purchase of a second system by the
 Whitehead Institute/Center for Genome Research, the world's largest public
 genome research center, and initial purchases by Galileo Genomics and an
 undisclosed party.
     SEQUENOM continues to sell MassARRAY systems to leading genomic and
 diagnostic companies and institutions, capitalizing on the momentum that
 started with the product's commercial launch in early 2000.  The MassARRAY
 system is the Company's proprietary platform for high-throughput analysis of
 genetic variations, or single nucleotide polymorphisms (SNPs), and the
 cornerstone of SEQUENOM's Systems business unit.  The system is also the
 enabling platform used by the Company's Genomics business unit for identifying
 SNPs and genes that significantly impact health.
     "The marketplace has confirmed that our MassARRAY system is the platform
 of choice for groups serious about undertaking large-scale genetic studies,"
 said Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer.  "In
 the past year, our systems business has seen demand steadily increase as the
 leading genomics companies and research institutions from around the world
 discover the advantages of our technology and services.
     "Our customers also recognize that we provide a comprehensive solution for
 determining the medical utility of SNPs and genes," continued Schuh.  "This is
 enabled by our ability to conduct full genome screens, which is the analysis
 of many genes in many people.  In addition to the MassARRAY system, our
 automated assay design process, the power to combine or pool hundreds of
 samples in a single reaction to determine the frequency of genetic markers and
 an in-house DNA bank for a control population make such projects a reality
 today."
 
     About the Whitehead Institute
     The Whitehead Institute is a non-profit, independent basic research and
 teaching institution recognized worldwide for pathfinding programs in cancer
 and AIDS research, developmental biology, structural biology, infectious
 disease, and genetics.  The Institute's mission is to improve human health and
 welfare and extend the boundaries of knowledge for future generations.
 
     About Galileo Genomics
     Galileo Genomics is a population genomics company dedicated to the
 discovery of disease-susceptibility genes in common human diseases through the
 application of genetics to founder populations using cutting-edge
 technologies.  Galileo's research relies on the study of genetic data
 collected from the Quebec Founder Population, a population of 6 million
 distantly related individuals descended from a small group of roughly
 2,500 common ancestors that arrived from France between 1608 and 1760.
 
     About SEQUENOM
     SEQUENOM is leading a worldwide effort to identify genes and genetic
 variations with significant impact on human health.  Using its innovative
 technologies, information and scientific strategy, the Company is rapidly
 translating data generated from the Human Genome Project into medically
 important applications.  Breaking through the limitations of traditional
 research, SEQUENOM's MassARRAY technology, assay database, population genetics
 approach and ability to perform full genome screens are generating results
 that position SEQUENOM and its customers and collaborators to quickly capture
 novel leads to utilize in new genetics-based diagnostics, drugs and therapies.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the Securities Exchange Act
 of 1934, as amended.  Such forward-looking statements are subject to factors
 that could cause actual results to differ materially for SEQUENOM from those
 projected.  Those factors include risks and uncertainties relating to
 technological approaches, dependence on collaborative partners, the specific
 results generated and successful performance under these and other
 collaborative agreements, product development, manufacturing, market
 acceptance, cost and pricing of SEQUENOM products, competition, the
 intellectual property of others, patent protection and other risk factors
 discussed from time to time in SEQUENOM's reports and filings with the
 Securities and Exchange Commission, including SEQUENOM's Annual Report on Form
 10-K for the year ended December 31, 1999 and most recent Quarterly Report on
 Form 10-Q.  SEQUENOM expressly disclaims any obligation or undertaking to
 release publicly any updates or revisions to any forward-looking statements
 contained herein to reflect any change in SEQUENOM's expectations with regard
 thereto or any change in events, conditions, or circumstances on which any
 such statements are based.
 
 

SOURCE SEQUENOM, Inc.
    SAN DIEGO, April 4 /PRNewswire/ -- SEQUENOM(TM), Inc. (Nasdaq: SQNM) today
 announced that it has sold three additional MassARRAY systems, increasing the
 Company's installed base of systems at customer sites to 29 worldwide.  The
 three additional sales include the purchase of a second system by the
 Whitehead Institute/Center for Genome Research, the world's largest public
 genome research center, and initial purchases by Galileo Genomics and an
 undisclosed party.
     SEQUENOM continues to sell MassARRAY systems to leading genomic and
 diagnostic companies and institutions, capitalizing on the momentum that
 started with the product's commercial launch in early 2000.  The MassARRAY
 system is the Company's proprietary platform for high-throughput analysis of
 genetic variations, or single nucleotide polymorphisms (SNPs), and the
 cornerstone of SEQUENOM's Systems business unit.  The system is also the
 enabling platform used by the Company's Genomics business unit for identifying
 SNPs and genes that significantly impact health.
     "The marketplace has confirmed that our MassARRAY system is the platform
 of choice for groups serious about undertaking large-scale genetic studies,"
 said Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer.  "In
 the past year, our systems business has seen demand steadily increase as the
 leading genomics companies and research institutions from around the world
 discover the advantages of our technology and services.
     "Our customers also recognize that we provide a comprehensive solution for
 determining the medical utility of SNPs and genes," continued Schuh.  "This is
 enabled by our ability to conduct full genome screens, which is the analysis
 of many genes in many people.  In addition to the MassARRAY system, our
 automated assay design process, the power to combine or pool hundreds of
 samples in a single reaction to determine the frequency of genetic markers and
 an in-house DNA bank for a control population make such projects a reality
 today."
 
     About the Whitehead Institute
     The Whitehead Institute is a non-profit, independent basic research and
 teaching institution recognized worldwide for pathfinding programs in cancer
 and AIDS research, developmental biology, structural biology, infectious
 disease, and genetics.  The Institute's mission is to improve human health and
 welfare and extend the boundaries of knowledge for future generations.
 
     About Galileo Genomics
     Galileo Genomics is a population genomics company dedicated to the
 discovery of disease-susceptibility genes in common human diseases through the
 application of genetics to founder populations using cutting-edge
 technologies.  Galileo's research relies on the study of genetic data
 collected from the Quebec Founder Population, a population of 6 million
 distantly related individuals descended from a small group of roughly
 2,500 common ancestors that arrived from France between 1608 and 1760.
 
     About SEQUENOM
     SEQUENOM is leading a worldwide effort to identify genes and genetic
 variations with significant impact on human health.  Using its innovative
 technologies, information and scientific strategy, the Company is rapidly
 translating data generated from the Human Genome Project into medically
 important applications.  Breaking through the limitations of traditional
 research, SEQUENOM's MassARRAY technology, assay database, population genetics
 approach and ability to perform full genome screens are generating results
 that position SEQUENOM and its customers and collaborators to quickly capture
 novel leads to utilize in new genetics-based diagnostics, drugs and therapies.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the Securities Exchange Act
 of 1934, as amended.  Such forward-looking statements are subject to factors
 that could cause actual results to differ materially for SEQUENOM from those
 projected.  Those factors include risks and uncertainties relating to
 technological approaches, dependence on collaborative partners, the specific
 results generated and successful performance under these and other
 collaborative agreements, product development, manufacturing, market
 acceptance, cost and pricing of SEQUENOM products, competition, the
 intellectual property of others, patent protection and other risk factors
 discussed from time to time in SEQUENOM's reports and filings with the
 Securities and Exchange Commission, including SEQUENOM's Annual Report on Form
 10-K for the year ended December 31, 1999 and most recent Quarterly Report on
 Form 10-Q.  SEQUENOM expressly disclaims any obligation or undertaking to
 release publicly any updates or revisions to any forward-looking statements
 contained herein to reflect any change in SEQUENOM's expectations with regard
 thereto or any change in events, conditions, or circumstances on which any
 such statements are based.
 
 SOURCE  SEQUENOM, Inc.